RNA therapeutics are rapidly reshaping drug discovery, expanding opportunities far beyond mRNA vaccines. This panel brings together industry leaders and investors to explore how scientific innovation is translated into clinical and commercial success. From advances in RNA chemistry and delivery to manufacturing scale-up and funding strategies, panelists will share insights on key challenges and opportunities shaping the next wave of RNA-based medicines.
Tuesday, May 5, 13:00 - 13:45, room Shanghai 3+4
| Name | Position | Institution |
|---|---|---|
| Dave Madge | Vice President, Discovery Services | WuXi AppTec |
| Name | Position | Institution |
|---|---|---|
| Keith Philipps | Vice President Head of Grunenthal Genetic Medicine | Grunenthal |
| Hans Kistemaker | Director Chemistry and Drug Substance Manufacturing | ProQR Therapeutics |
| Samir Ounzain | CEO | Haya Therapeutics |
| Sara Trifari | CSO | T-ONE Therapeutics |
| Tiziana Rossetti | Principal | Sofinnova Partners |
| Anne Grahl | Investment Manager | Pureos Bioventures |
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for p
